These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 18373709

  • 1. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L, Walsby E, Gilkes A, Tonks A, Walsh V, Mills K, Burnett A, Rowntree C.
    Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
    [Abstract] [Full Text] [Related]

  • 2. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
    Reikvam H, Hatfield KJ, Ersvaer E, Hovland R, Skavland J, Gjertsen BT, Petersen K, Bruserud O.
    Br J Haematol; 2012 Feb; 156(4):468-80. PubMed ID: 22150087
    [Abstract] [Full Text] [Related]

  • 3. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
    Nishioka C, Ikezoe T, Yang J, Takeuchi S, Koeffler HP, Yokoyama A.
    Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
    [Abstract] [Full Text] [Related]

  • 4. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor.
    Yu W, Wang J, Jin J, Qian W, Qian J, Cheng Y, Wang L.
    Leuk Res; 2011 Sep; 35(9):1212-8. PubMed ID: 21632108
    [Abstract] [Full Text] [Related]

  • 5. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ, Lazenby M, Pepper CJ, Knapper S, Burnett AK.
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E, Barbarroja N, Torres LA, Buendía P, Velasco F, Dorado G, Torres A, López-Pedrera C.
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [Abstract] [Full Text] [Related]

  • 7. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, Wang J.
    Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
    [Abstract] [Full Text] [Related]

  • 8. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
    George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Fiskus W, Scuto A, Annavarapu S, Moscinski L, Bhalla K.
    Cancer Res; 2004 May 15; 64(10):3645-52. PubMed ID: 15150124
    [Abstract] [Full Text] [Related]

  • 9. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT, Levis M, Small D.
    Br J Haematol; 2006 Sep 15; 134(5):500-9. PubMed ID: 16869825
    [Abstract] [Full Text] [Related]

  • 10. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.
    Cancer Lett; 2009 Oct 18; 284(1):62-70. PubMed ID: 19464103
    [Abstract] [Full Text] [Related]

  • 11. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.
    Exp Hematol; 2010 Aug 18; 38(8):641-52. PubMed ID: 20380868
    [Abstract] [Full Text] [Related]

  • 12. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
    Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC.
    Br J Haematol; 2007 Dec 18; 139(5):837-44. PubMed ID: 17949452
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr 18; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 14. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S.
    Cancer Res; 2003 Dec 01; 63(23):8420-7. PubMed ID: 14679005
    [Abstract] [Full Text] [Related]

  • 15. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
    Pelicano H, Carew JS, McQueen TJ, Andreeff M, Plunkett W, Keating MJ, Huang P.
    Leukemia; 2006 Apr 01; 20(4):610-9. PubMed ID: 16482209
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
    Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, Kersey JH.
    Clin Cancer Res; 2003 Oct 01; 9(12):4483-93. PubMed ID: 14555522
    [Abstract] [Full Text] [Related]

  • 18. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
    Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A.
    J Exp Ther Oncol; 2008 Oct 01; 7(3):183-93. PubMed ID: 19066127
    [Abstract] [Full Text] [Related]

  • 19. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.
    Clin Cancer Res; 2006 Nov 15; 12(22):6826-35. PubMed ID: 17121904
    [Abstract] [Full Text] [Related]

  • 20. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.
    Yao Q, Weigel B, Kersey J.
    Clin Cancer Res; 2007 Mar 01; 13(5):1591-600. PubMed ID: 17332306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.